Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07314723) titled '9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer' on Dec. 18, 2025.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Condition:
Urothelial Carcinoma
Intervention:
Drug: 9MW2821
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 1, 2025
Target Sample Size: 90
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07314723
Published b...